Carocellbio
1 known investors
Carocell Bio develops peptide-based anti-inflammatory therapeutics, including its lead peptide JEL0305, that inhibit the intracellular MAPK (p38) inflammatory pathway and are combined with a nanoparticle delivery technology for topical application to the skin. It targets inflammatory conditions such as eczema (atopic dermatitis) and inflammation-related skin ageing.
Founders & leadership
MD
Mike DaviesCEO & Founder
AG
Ashley GeorgeInterim Chairman & Financial Director
Investors Β· 1
Frequently asked questions
- What does Carocellbio do?
- Carocell Bio develops peptide-based anti-inflammatory therapeutics, including its lead peptide JEL0305, that inhibit the intracellular MAPK (p38) inflammatory pathway and are combined with a nanoparticle delivery technology for topical application to the skin. It targets inflammatory conditions such as eczema (atopic dermatitis) and inflammation-related skin ageing.
- Who founded Carocellbio?
- Carocellbio was founded by Mike Davies.
- Who are Carocellbio's investors?
- Carocellbio's investors include Deepbridge Capital.